Buscar en
Angiología
Toda la web
Inicio Angiología Relación de la dilatación de la arteria braquial mediada por flujo y el índic...
Información de la revista
Vol. 59. Núm. 1.
Páginas 55-61 (Enero 2007)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 59. Núm. 1.
Páginas 55-61 (Enero 2007)
Acceso a texto completo
Relación de la dilatación de la arteria braquial mediada por flujo y el índice tobillo-brazo en pacientes con enfermedad arterial periférica
The relation between brachial artery flow-mediated dilation and the ankle-brachial index in patients with peripheral arterial disease
Visitas
3572
F.J. Medina-Maldonado
Autor para correspondencia
fjmedina@telefonica.net

Correspondencia: Corona, 24, 6.º-B. E-28054 Madrid.
, J. de Haro-Miralles, E. Martínez-Aguilar, A. Flórez-González, J.R. March-García, F. Acín
Servicio de Angiología y Cirugía Vascular. Hospital Universitario de Getafe. Getafe, Madrid, España
Este artículo ha recibido
Información del artículo
Resumen
Introducción

La medida ecográfica de la dilatación de la arteria braquial mediada por flujo (DABMF) se ha validado en nuestro laboratorio en la determinación de la disfunción endotelial en pacientes con enfermedad arterial periférica (EAP). Según nuestra experiencia, esta disfunción no es determinante de la gravedad de la enfermedad. El índice tobillo-brazo (ITB) es un marcador clásico de EAP asociado a su gravedad.

Objetivo

Determinar la relación de la DABMF y el ITB en pacientes con EAP.

Pacientes y métodos

Determinamos la DABMF y el ITB en pacientes con EAP sintomática, demostrada hemodinámica y/o angiográficamente con ITB < 0,9. Se recogen los factores de riesgo cardiovascular y los tratamientos.

Resultados

Se reclutó un total de 72 pacientes con edad de 65,36 ± 7,7 años, de los que un 27,5% presentaba isquemia crítica. La DABMF fue de 5,49 ± 0,43%; el coeficiente de correlación de Spearman es r < 0,001 (p < 0,05). No existieron diferencias estadísticamente significativas en la DABMF entre el grupo con ITB < 0,3 (percentil 5) y el de índice mayor. Tampoco existió en los valores de ITB de los grupos con DABMF mayor y menor a 1,35% (percentil 5).

Conclusiones

No existe relación directa entre el ITB y la DABMF, lo que corrobora nuestra hipótesis de que la disfunción endotelial es un factor predisponente para el desarrollo de la EAP, pero no determinante en su gravedad.

Palabras clave:
Arteriosclerosis
Dilatación braquial
Disfunción endotelial
Enfermedad arterial periférica
Índice tobillo-brazo
Ultrasonidos
Summary
Introduction

Measurement of brachial artery flow-mediated dilation (BAFMD) using ultrasonography was tested in our laboratory to determine endothelial dysfunction in patients with peripheral arterial disease (PAD). Our experience shows that this dysfunction does not determine the severity of the disease. The ankle-brachial index (ABI) is a classic marker of PAD associated with its severity.

Aim

To determine the BAFMD and the ABI in patients with PAD.

Patients and methods

The BAFMD and ABI were determined in patients with symptomatic PAD, which had been confirmed haemodynamically and/or angiographically with an ABI < 0.9. Both cardiovascular risk factors and treatments are considered.

Results

A total of 72 patients aged 65.36 ± 7.7 years were recruited for the study, 27.5% of whom had critical ischaemia. BAFMD was 5.49 ± 0.43% and the Spearman correlation coefficient was r < 0.001 (p < 0.05). No statistically significant differences were found between the BAFMD in the group with an ABI < 0.3 (percentile 5) and the one with a higher index. No significant differences were observed in the ABI values in the groups with a BAFMD above and below 1.35% (percentile 5).

Conclusions

There is no direct relation between the ABI and the BAFMD, which lends support to our hypothesis that endothelial dysfunction is a predisposing factor for the development of PAD, but does not determine its severity.

Key words:
Ankle-brachial index
Arteriosclerosis
Brachial artery dilation
Endothelial dysfunction
Peripheral arterial disease
Ultrasounds
El Texto completo está disponible en PDF
Bibliografíca
[1.]
Davignon J., Ganz P..
Role of endothelial dysfunction in atherosclerosis.
[2.]
Barbato J.E., Tzeng E..
Nitric oxide and arterial disease.
J Vasc Surg., 40 (2004), pp. 187-193
[3.]
Healy B..
Endotelial cell dysfunction: an emerging endocrinopathy linked to the coronary disease.
J Am Coll Cardiol., 16 (1990), pp. 357-358
[4.]
Anderson T.J., Uehata A., Gerhard M.D., Meredith I.T., Knab S., Delagrange D., et al.
Close relation of endothelial function in the human coronary and peripheral circulations.
J Am Coll Cardiol., 26 (1995), pp. 1235-1241
[5.]
Celermajer D.S., Sorensen K.E., Bull C., Robinson J., Deanfield J.E..
Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction.
J Am Coll Cardiol., 24 (1994), pp. 1468-1474
[6.]
Schmieder J.S..
Impaired endothelial function in arterial hypertension and hypercholesterolemia, potential mechanisms and differences.
J Hypertens, 18 (2000), pp. 363-374
[7.]
Jarvisalo M.J., Raitakari M., Toikka J.O., Putto-Laurila A., Rontu R., Laine S., et al.
Endothelial dysfunction and increased arterial intima-media thickness in children with type 1 diabetes.
Circulation, 109 (2004), pp. 1750-1755
[8.]
Celermajer D.S., Sorensen K., Georgakopoulos D., Bull C., Thomas O., Robinson J., et al.
Cigarette smoking is associated with doserelated and potentially reversible impairment of endothelium-dependent dilation in healthy young adults.
Circulation, 88 (1993), pp. 2149-2155
[9.]
Schroeder S., Enderle M.D., Ossen R., Meisner C., Baumbach A., Pfohl M., et al.
Noninvasive determination of endothelium-mediated vasodilatation as a screening test for coronary artery disease: pilot study to assess the predictive value in comparison imaging.
Am Heart J., 138 (1999), pp. 731-739
[10.]
Neunteufl T., Heher S., Katzenschlager R., Wolfl G., Kostner K., Maurer G., et al.
Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain.
Am J Cardiol., 86 (2000), pp. 207-210
[11.]
Criqui M.H., Langer R.D., Fronek A., Feigelson H.S., Klauber M.R., McCann T.J., et al.
Mortality over a period of 10 years in patients with peripheral arterial disease.
N Engl J Med., 326 (1992), pp. 381-386
[12.]
Newman A.B., Shemanski L., Manolio T.A., Cushman M., Mittelmark M., Polak J.F., et al.
Anklearm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group.
Arterioscler Thromb Vasc Biol., 19 (1999), pp. 538-545
[13.]
Celermajer D.S., Sorensen K.E., Gooch V.M..
Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis.
Lancet, 340 (1992), pp. 1111-1115
[14.]
Joannides R., Haefeli W.E., Linder L., Richard V., Bakkali E.H., Thuillez C., et al.
Nitric oxide is responsible for flow-dependent dilation of human peripheral conduit arteries in vivo.
Circulation, 91 (1995), pp. 1314-1319
[15.]
Kobayashi K., Akishita M., Yu W., Hashimoto M., Ohni M., Toba K..
Interrelationship between non invasive measurements of atherosclerosis: flow-mediated dilation of brachial artery, carotid intima-media thickness and pulsewave velocity.
Atherosclerosis, 173 (2004), pp. 13-18
[16.]
Corretti M.C., Anderson T.J., Benjamin E.J., Celermajer D., Charbonneau F., Creager M.A., et al.
Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilatation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force.
J Am Coll Cardiol., 39 (2002), pp. 257-265
[17.]
Liang Y.L., Teede H., Kotsopoulos D., Shiel L., Cameron J.D., Dart A.M., et al.
Non-invasive measurements of arterial structure and function: repeatability, interrelationships and trial sample size.
Clin Sci, 95 (1998), pp. 669-679
[18.]
Medina F., De Haro J., March J.R., Martínez-Aguilar E., López-Quintana A., Acín F..
Relación de la disfunción endotelial medida por un método no invasivo y la enfermedad arterial periférica [abstract].
Angiología, 57 (2005), pp. 288
[19.]
Brevetti G., Silvestro A., Giacomo S., Bucur R., Donato A.M., Schiano V., et al.
Endothelial dysfunction in peripheral arterial disease is related to increase in plasma markers of inflammation and severity of peripheral circulatory impairment but not to classic risk factors and atherosclerotic burden.
J Vasc Surg., 38 (2003), pp. 374-379
[20.]
Yataco A.R., Corretti M.C., Gardner A.W., Womack C.J., Katzel L.I..
Endotelial reactivity and cardiac risk factors in older patients with peripheral arterial disease.
Am J Cardiol., 83 (1999), pp. 754-758
[21.]
Brevetti G., Martone V.D., De Cristoforo T., Corrado S., Silvestro A., Di Donato A.M., et al.
High levels of adhesion molecules are associated with impaired endothelium-dependent vasodilatation in patients with peripheral arterial disease.
Thromb Haemost, 85 (2001), pp. 63-66
[22.]
Poredos P., Golob M., Jensterle M..
Interrelationship between peripheral arterial occlusive disease, carotid atherosclerosis and flow-mediated dilation of the brachial artery.
Int Angiol., 22 (2003), pp. 83-87
[23.]
Silvestro A., Scopacasa F., Oliva G., De Cristofaro T., Iuliano L., Brevetti G..
Vitamin C prevents endothelial dysfunction induced by acute exercise in patients with intermittent claudication.
Atherosclerosis, 165 (2002), pp. 277-283
[24.]
Brendle D.C., Joseph L.J., Corretti M.C., Gardner A.W., Katzel L.I..
Effects of exercise rehabilitation on endothelial reactivity in older patients with peripheral arterial disease.
Am J Cardiol., 87 (2001), pp. 324-329
[25.]
Yu H.I., Sheu W.H., Lai C.J., Lee W.J., Chen Y.T..
Endothelial dysfunction in type 2 diabetes mellitus subjects with peripheral artery disease.
Int J Cardiol., 78 (2001), pp. 19-25
[26.]
Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.
Diabetes Care, 24 (2001), pp. S5-S20
[27.]
Verdecchia P., Angeli F..
The Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the weapons are ready.
Rev Esp Cardiol., 56 (2003), pp. 843-847
[28.]
National Heart, Lung, and Blood Institute. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III, or ATP III). URL: http://www.nhlbi.nih.gov/guidelines/cholesterol/atglance.htm. [25.02.2006].
[29.]
Ferrer R., Hernández-Jara J..
Chronic renal insufficiency. I: definition, clinical course stages, progression mechanisms, etiology, and diagnostic criteria.
Nefrologia, 21 (2001), pp. 18-20
[30.]
Gokce N., Keaney J.F. Jr, Hunter L.M., Watkins M.T., Nedeljkovic Z.S., Menzoian J.O., et al.
Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease.
J Am Coll Cardiol., 41 (2003), pp. 1769-1775
[31.]
Brevetti G., Silvestro A., Schiano V., Chiariello M..
Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle-brachial pressure index.
Circulation, 108 (2003), pp. 2093-2098
[32.]
O'Leary D.H., Polak J.F., Kronmal R.A., Manolio T.A., Burke G.L., Wolfson S.K..
Carotid-artery intima an media thickness as a risk factor for myocardial infarctation and stroke in older adults.
N Engl J Med., 340 (1999), pp. 14-22
[33.]
Furberg C.D., Admas H.P., Applegate W.B., Byington R.P., Espeland M.A., Hartwell T., et al.
Coronary heart disease/myocardial infarctation: effect of lovastatin on early atherosclerosis and cardiovascular events.
Circulation, 90 (1994), pp. 1679-1687
[34.]
De Gennaro-Colonna V., Fioretti S., Rigamonti A., Bonomo S., Manfredi B., Muller E.E., et al.
Angiotensin II type 1 receptor antagonism improves endothelial vasodilator function in L-NAME-induced hypertensive rats by a kinin-dependent mechanism.
J Hypertens, 24 (2006), pp. 95-102
Copyright © 2007. SEACV
Opciones de artículo
Herramientas
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos